HCV without cirrhosis: GLE + PIB highly effective across all genotypes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Once-daily glecaprevir + pibrentasvir (GLE+PIB) is highly effective for clearing all HCV genotypes (GTs) in patients without cirrhosis, whether treatment-naïve or previously treated with peginterferon/ribavirin (PR).

Why this matters

  • Both components—a pangenotypic NS3/4A pr...